Close Menu

NEW YORK − Genprex said Wednesday that after receiving the US Food and Drug Administration's fast track designation last month for its immunogene therapy Oncoprex in combination with the EGFR tyrosine kinase inhibitor (TKI) osimertinib (AstraZeneca’s Tagrisso), the clinical-stage gene therapy company is prioritizing development of this therapy combination for EGFR-mutated non-small cell lung cancer and will start enrollment in Phase I/II clinical trials in mid-2020.

Enrollment will start after the FDA accepts Genprex's amendment to its investigational new drug application.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.